Abstract：
BACKGROUND: This systematic review aims to compare the prognosis of treatment transarterial chemoembolization (TACE) combined with sorafenib and TACE-alone in patients with hepatocellular carcinoma (HCC) with Barcelona clinic liver cancer-stage C (BCLC-C).
METHODS: A systematic search was conducted on five electronic databases: PubMed, ScienceDirect, Cochrane, Embase, and Scopus. Studies were included if they compared overall survival (OS) of TACE-Sorafenib to TACE-alone in patients with HCC BCLC-C within the 2019-2023 timeframe. We excluded studies consisting of conference abstracts, letters, editorials, guidelines, case reports, animal studies, trial registries, and unpublished work. The selected articles were evaluated from August 2023 to September 2023. The journal\'s quality was assessed with NOS for a non-randomized controlled trial.
RESULTS: This systematic review included four studies following the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA). All four studies compared the OS of 401 patients with TACE-sorafenib to TACE-alone. Two studies compared time-to-progression (TTP), one study compared progression-free survival (PFS), and two studies compared disease control rate (DCR). There were various population criteria, TACE techniques used, risk factors, follow-up time, and adverse events. The collected evidence generally suggested that the combination of TACE-sorafenib is superior compared to TACE-alone. Due to a lack of essential data for the included study, a meta-analysis couldn\'t be performed.
CONCLUSIONS: The results of this systematic review suggested that TACE-sorafenib combination therapy in patients with HCC BCLC-C improves OS superior compared to TACE-alone, without a notable increase in adverse events.
METHODS: A systematic search was conducted on five electronic databases: PubMed, ScienceDirect, Cochrane, Embase, and Scopus. Studies were included if they compared overall survival (OS) of TACE-Sorafenib to TACE-alone in patients with HCC BCLC-C within the 2019-2023 timeframe. We excluded studies consisting of conference abstracts, letters, editorials, guidelines, case reports, animal studies, trial registries, and unpublished work. The selected articles were evaluated from August 2023 to September 2023. The journal\'s quality was assessed with NOS for a non-randomized controlled trial.
RESULTS: This systematic review included four studies following the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA). All four studies compared the OS of 401 patients with TACE-sorafenib to TACE-alone. Two studies compared time-to-progression (TTP), one study compared progression-free survival (PFS), and two studies compared disease control rate (DCR). There were various population criteria, TACE techniques used, risk factors, follow-up time, and adverse events. The collected evidence generally suggested that the combination of TACE-sorafenib is superior compared to TACE-alone. Due to a lack of essential data for the included study, a meta-analysis couldn\'t be performed.
CONCLUSIONS: The results of this systematic review suggested that TACE-sorafenib combination therapy in patients with HCC BCLC-C improves OS superior compared to TACE-alone, without a notable increase in adverse events.
摘要：
背景：本系统评价旨在比较巴塞罗那临床肝癌C期（BCLC-C）的肝细胞癌（HCC）患者经肝动脉化疗栓塞（TACE）联合索拉非尼和TACE单独治疗的预后。
方法：对五个电子数据库进行了系统搜索：PubMed，ScienceDirect,科克伦,Embase,还有Scopus.如果他们在2019-2023年时间框架内比较TACE-索拉非尼与TACE单独治疗HCCBCLC-C患者的总生存期（OS），则纳入研究。我们排除了由会议摘要组成的研究，信件,社论,指导方针,病例报告,动物研究,审判登记处，和未发表的作品。从2023年8月至2023年9月对选定的文章进行了评估。在一项非随机对照试验中，使用NOS评估该杂志的质量。
结果：本系统评价包括4项系统评价和Meta分析（PRISMA）首选报告项目后的研究。所有四项研究都比较了401例TACE-索拉非尼与TACE单独治疗患者的OS。两项研究比较了进展时间（TTP），一项研究比较了无进展生存期（PFS），两项研究比较了疾病控制率（DCR）。有不同的人口标准，使用的TACE技术，危险因素，随访时间,和不良事件。收集的证据通常表明TACE-索拉非尼的组合优于单独的TACE。由于纳入研究缺乏必要的数据，无法进行荟萃分析。
结论：这项系统评价的结果表明，与单独使用TACE相比，TACE-索拉非尼联合治疗BCLC-CHCC患者的OS改善优于TACE，没有显著增加的不良事件。
方法：对五个电子数据库进行了系统搜索：PubMed，ScienceDirect,科克伦,Embase,还有Scopus.如果他们在2019-2023年时间框架内比较TACE-索拉非尼与TACE单独治疗HCCBCLC-C患者的总生存期（OS），则纳入研究。我们排除了由会议摘要组成的研究，信件,社论,指导方针,病例报告,动物研究,审判登记处，和未发表的作品。从2023年8月至2023年9月对选定的文章进行了评估。在一项非随机对照试验中，使用NOS评估该杂志的质量。
结果：本系统评价包括4项系统评价和Meta分析（PRISMA）首选报告项目后的研究。所有四项研究都比较了401例TACE-索拉非尼与TACE单独治疗患者的OS。两项研究比较了进展时间（TTP），一项研究比较了无进展生存期（PFS），两项研究比较了疾病控制率（DCR）。有不同的人口标准，使用的TACE技术，危险因素，随访时间,和不良事件。收集的证据通常表明TACE-索拉非尼的组合优于单独的TACE。由于纳入研究缺乏必要的数据，无法进行荟萃分析。
结论：这项系统评价的结果表明，与单独使用TACE相比，TACE-索拉非尼联合治疗BCLC-CHCC患者的OS改善优于TACE，没有显著增加的不良事件。
